CN105481725B - The crystal form and preparation method thereof of L-arginine phenylacetate - Google Patents
The crystal form and preparation method thereof of L-arginine phenylacetate Download PDFInfo
- Publication number
- CN105481725B CN105481725B CN201410475736.4A CN201410475736A CN105481725B CN 105481725 B CN105481725 B CN 105481725B CN 201410475736 A CN201410475736 A CN 201410475736A CN 105481725 B CN105481725 B CN 105481725B
- Authority
- CN
- China
- Prior art keywords
- arginine
- phenylacetate
- crystal form
- preparation
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention provides a kind of crystal forms and preparation method thereof of L-arginine phenylacetate.The X-ray powder diffraction figure of the crystal form has absorption peak 7.2 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.1 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.7 ° of ± 0.2 ° of positions including 2 θ；The preparation method of the crystal form includes by L-arginine phenylacetate in C1~3Alcoholic solution is dissolving crystallized, obtains the crystal form.Stability of crystal form prepared by the present invention is good, and preparation method is easy to operate, reproducible, is suitble to industrialized production.
Description
Technical field
The present invention relates to pharmaceutical technology fields, and in particular to a kind of crystal form of L-arginine phenylacetate and its preparation side
Method.
Background technique
L-arginine phenylacetate molecular formula is C8H8O2·C6H14N4O2, structural formula such as following formula I:
。
It is known in addition to hyperammonemia caused by arginase defect, remaining hyperammonemia case can be used arginine and control
It treats, arginine not only can promote the discharge of ammonia, but also supplement internal essential amino acid.Arginine participates in ornithine in human body and follows
Ring promotes the formation of urea, makes one the ammonia generated in vivo, is transformed into nontoxic urea through ornithine circulation, by being discharged in urine, from
And reduce ammonia concentration；When hepatosis, human body is mainly to reduce blood ammonia by the synthesis of glutamine.It is excessive in vivo
Glutamine it is not only unfavorable to human body, but also can enteron aisle decompose generate ammonia ammonia concentration is gone up.Sodium phenylacetate and paddy
Propylhomoserin is easy to be discharged from urine in conjunction with phenylacetyl glutamic acid is formed, to reduce the toxic level of ammonia.
Leonard J V and Morris A A M is in document Urea cycle disorders(Semin Neonatol
2002;Phenylacetate, benzenebutanoic acid salt and arginine are disclosed in 7:27-35) to be used in combination, and can be used for treating hyperammonemia；
Document Alternative pathway therapy for urea cycle disorders:Twenty years later
(St. Louis, MO, United States. Journal of Pediatrics, 2001, Volume:138, Issue:
1, Pages:S46-S55) it discloses sodium phenylacetate to be used in combination with arginine, for treating hyperammonemia.
At present when clinical use arginine hydrochloride injection treatment hyperammonemia, hyperchloremic acidosis and blood can be caused
The side reactions such as middle urea, creatine, creatine concentration raising, thus limit its use in hyperchloremic acidosis patient.
In addition, some salts (such as arginine monohydrochloride, sodium phenylacetate, phenylbutyrate sodium), especially sodium salt or chloride salt,
When they are for treating disease (such as hepatic encephalopathy) related with hepatopathy, there are disadvantages.Firstly, since certain salts (such as sodium
Salt) intake of high concentration is to endanger very much to the hepatopath that inherently may have ascites, body fluid overload or electrolyte imbalance
Danger；Secondly as increasing for osmotic pressure is more difficult from so that being injected intravenously, and diluted by tank solution again for vein
Injection then will cause fluid overload again.Therefore, disease related with hepatopathy can effectively be prevented or be treated to urgent clinical needs one kind
(such as hepatic encephalopathy), and it is avoided that the drug of above-mentioned side effect.
The present inventor is found surprisingly that, L-arginine phenylacetate (compound shown in Formulas I), when treating hyperammonemia,
With synergistic effect, and it can significantly overcome defect when L-arginine and phenylacetic acid or sodium phenylacetate exclusive use.
The present inventor is found through experiments that, L-arginine and corresponding carboxylic acid mild heat in ethanol are vigorously stirred
After reaction, by evaporating solvent under reduced pressure, obtained product L-arginine phenylacetate is unstable, is easy the moisture absorption, and repeat
Property it is poor, be not suitable for industrialization generate.
Currently without the document report about L-arginine phenylacetate crystal form.Also, many documents teach many medicines
The amorphous and crystal habit of object shows different solubility and different bioavilabilities, so that it is living to generate different biologies
Property.The drug of crystal habit is better than nodeless mesh form above-mentioned in nature under normal circumstances, has preferable physics and chemistry steady
It is qualitative, there is very big benefit in terms of preparation.Therefore it needs to study many kinds of solids form of L-arginine phenylacetate.
Summary of the invention
It is an object of that present invention to provide a kind of novel crystal forms of L-arginine phenylacetate, the X-ray powder of the crystal form spreads out
Penetrating figure has absorption peak 7.1 ° ± 0.2 °, 14.2 ° ± 0.2 °, 18.1 ° ± 0.2 °, 21.4 ° of ± 0.2 ° of positions including 2 θ.
The crystal form of the L-arginine phenylacetate, X-ray powder diffraction figure include 2 θ 7.1 ° ±
0.2°、14.2°±0.2°、18.1°±0.2°、19.0°±0.2°、20.3°±0.2°、21.4°±0.2°、23.9°±0.2°
There is absorption peak in position.
Further, the crystal form of the L-arginine phenylacetate, X-ray powder diffraction figure include that 2 θ exist
7.1°±0.2°、11.1°±0.2°、11.8°±0.2°、13.1°±0.2°、14.2°±0.2°、15.2°±0.2°、16.5°
± 0.2 °, 18.1 ° ± 0.2 °, 19.0 ° ± 0.2 °, 20.3 ° ± 0.2 °, 21.4 ° ± 0.2 °, 23.9 ° of ± 0.2 ° of positions have absorption
Peak, wherein the crystal form of the L-arginine phenylacetate has X-ray powder diffraction figure as shown in Figure 1.
On the other hand, the present invention provides the preparation methods of the crystal form of the L-arginine phenylacetate, it is characterised in that:
L-arginine phenylacetate is dissolved in C1~3It is crystallized in alcoholic solution, prepares the crystal form of L-arginine phenylacetate.Wherein, institute
The C stated1~3Alcohol is selected from methanol, ethyl alcohol, propyl alcohol or isopropanol；It is preferred that the C1~3The ethyl alcohol that alcoholic solution is 90% ~ 100% is water-soluble
Liquid.The method specifically includes the following steps:
L-arginine phenylacetate is added in 90% ~ 100% ethanol water of 2.5 ~ 12 times of w/vs, is heated
To reflux, the water of optional 1% ~ 12% ethyl alcohol volume of addition, stirring to solid is all dissolved, and is subsequently cooled to -20 DEG C ~ 30 DEG C,
- 5 DEG C ~ 5 DEG C are preferably cooled to, is more preferably cooled to 0 DEG C, continues 0.5 ~ 3h of stir about, filtering, 40 DEG C ~ 60 DEG C dryings obtain white
Color crystalline solid.
On the other hand, the preparation of the crystal form of L-arginine phenylacetate of the present invention can also by by L-arginine with
After phenylacetic acid or its reactant salt, C is directly added into reaction solution1~3Alcoholic solution carries out crystallization acquisition.Specifically include following step
It is rapid:
1) L-arginine and phenylacetic acid or its salt, are added to C with the molar ratio of 1:1 ~ 1:21~3In alcoholic solution, it is warming up to
10 ~ 80 DEG C, 40 DEG C are preferably warming up to, 0.1 ~ 5 hour, preferably reaction 2.0h are reacted in stirring；
2), C is added into the solution of step 1)1~3Alcoholic solution is heated to reflux to 5 ~ 20 times (v/w) of L-arginine to solid
Body is entirely molten, is cooled to -20 DEG C ~ 30 DEG C, is preferably cooled to -5 DEG C ~ 5 DEG C, optional addition or is added without crystal seed, stirs 0.5 ~ 3h,
Filtering, it is dry, obtain white solid.
Wherein, the C1~3Alcoholic solution is methanol, ethyl alcohol, the aqueous solution of propyl alcohol or isopropanol, preferred concentration is 90% ~
100%；The further preferred C1~3The ethanol solution that alcoholic solution is 90% ~ 100%.
Further, the C1~3Alcoholic solution be 98% ~ 100%(v/v) ethanol solution when, it is preferable that in step 2 plus
Heat be back to solid it is complete it is molten before, water (such as 0 ~ 12% v of appropriate volume is added into crystallizing systemAlcohol/vWater).
Wherein, the crystal seed of the L-arginine phenylacetate can be prepared by the following method acquisition:
L-arginine and phenylacetic acid are reacted in ethanol solution with the molar ratio of 1:1 ~ 1:1.2, are warming up to 10 DEG C ~ 80
DEG C, it stirs 0.1 ~ 5.0 hour, it is cooling, it filters, it is dry, obtain white solid, the as crystal seed of L-arginine phenylacetate.
Phenylacetic acid of the present invention or its salt, phenylacetate therein includes the univalent metal salt of phenylacetic acid, such as benzene second
Acid sodium-salt, sylvite etc..
On the other hand, the present invention also provides a kind of amorphous solid of L-arginine phenylacetate, the L-arginines
The crystal form comprising at least one characteristic peak, the spy is presented in the X-ray powder diffraction figure of the amorphous solid of phenylacetate
Levy peak be selected from 2 θ about 7.1 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.6 ± 0.2 °, 18.3 ° ± 0.2 °, 21.4 ° ± 0.2 °,
23.9°±0.2°。
Further, the X-ray powder diffraction spectrogram of the amorphous solid of the L-arginine phenylacetate such as attached drawing 2
It is illustrated.
On the other hand, the present invention also provides the preparation method of the amorphous solid of the L-arginine phenylacetate, packets
It includes:
By L-arginine (1.0eq.), it is added in ethyl alcohol, is stirred at room temperature；Into above-mentioned solution be added phenylacetic acid (1.0 ~
1.2eq), nitrogen protection is stirred at room temperature, until reaction solution becomes clarification, evaporating solvent under reduced pressure obtains white solid, X-ray powder
Last diffraction pattern is as shown in Fig. 2.
On the other hand, the present invention provides the crystal forms of the L-arginine phenylacetic acid in preparation prevention and/or treatment liver property
Purposes in the drug of encephalopathy；It is preferred that improving and/or treating the purposes in hyperammonemia drug in preparation.It is diagnosed including giving
The crystal form of the L-arginine phenylacetate provided by the invention of subject's effective dose with hepatic encephalopathy or hyperammonemia or
Its pharmaceutical composition containing therapeutically effective amount.The crystal form of the L-arginine phenylacetate or its pharmaceutical composition can take orally
Or intravenously administrable, wherein the therapeutically effective amount of oral administration is within the scope of about 500mg to about 50g；The treatment of intravenously administrable is effective
Dosage is no more than 500ml L-arginine phenylacetate solution, and the solution includes the L-arginine phenylacetic acid of at least 25mg/ml
Salt, and the solution and body fluid are isotonic.The usage and dosage of the L-arginine phenylacetate, can according to clinical needs,
It is determined according to method known to persons of ordinary skill in the art, it should be understood that these usages and dosage should not limit this hair
It is bright.
The L-arginine phenylacetate novel crystal forms that the present invention prepares are with good stability, experiments have shown that, for a long time
Storage (6 months or more) crystal form is basically unchanged, and L-arginine phenylacetate provided by the present invention does not contain sodium or chloride, because
This, it is contemplated that L-arginine phenylacetate provides the safety improved compared with other salt of L arginine and phenylacetic acid, with L- essence
Other salt such as propylhomoserin hydrochloride or sodium phenylacetate are compared and show lower toxicity, and therefore can be given with higher concentration vein.
L-arginine phenylacetate provided by the present invention is used for intravenously administrable, has insignificant sodium load, and therefore
So that required intravenous fluids amount is minimum；There is significant clinical improvement to stemness cerebropathy therapeutic.
In addition, the preparation method of the crystal form of L-arginine phenylacetate provided by the invention, easy to operate, it is reproducible,
Recrystallisation solvent is done using lower alcohol, production cost is low, and reaction condition is mild, and it is low for equipment requirements, it is suitble to industrialized production；And
And method provided by the invention, the L-arginine phenylacetate crystal form purity of preparation is high, and it is good to obtain stability of crystal form.
Detailed description of the invention
The X-ray powder diffraction figure of L-arginine phenylacetate crystal form is shown in Fig. 1.
The X-ray powder diffraction figure of L-arginine phenylacetate amorphous solid is shown in Fig. 2.
Specific embodiment
In order to which the technical problems, technical solutions and beneficial effects solved by the present invention is more clearly understood, below in conjunction with
Specific embodiment, the present invention is further illustrated.
In following embodiments, unless otherwise indicated, the test method is usually according to normal condition or manufacturer builds
The condition of view is implemented；L-arginine is bought in Anji chemically-resistant, purity: 99%；Phenylacetic acid purchase has in Chinese medicines group chemical reagent
Limit company, purity: 98%；Other raw materials used, reagent can be obtained by the method for commercially available purchase.
X-ray powder diffraction (XRPD) figure of the present invention is in Panalytical (Panaco) company
It is acquired on Empyrean type X-ray powder diffraction instrument；About 10mg sample is evenly laid out on monocrystal silicon sample disk, in 45kV
It is scanned with 40mA.
The preparation of the crystal form of 1 L-arginine phenylacetate of embodiment:
(1) preparation of L-arginine phenylacetate crystal seed: by L-arginine (3.48g, 20mmol) and phenylacetic acid
(2.99g, 22mmol) is dissolved in 99% ethyl alcohol (27.84ml), is warming up to 40 DEG C, has a large amount of solids to be precipitated, and stirs 2.0h, is cooled to
Room temperature, filtering, 40 DEG C of dry 2.0h, obtaining white solid, (5.86g, yield: 94.5%), as L-arginine phenylacetate is brilliant
Kind.
(2) preparation of the crystal form of L-arginine phenylacetate: by L-arginine (3.48g, 20mmol) and phenylacetic acid
(2.99g, 22mmol) is dissolved in 99% ethyl alcohol (20.88ml), is warming up to 40 DEG C, insulated and stirred 10min, has a large amount of solids to be precipitated,
It is added ethyl alcohol (7.0ml), is heated to flowing back, be added water (1.5ml), solid is entirely molten, is cooled to 0 DEG C, is added crystal seed (0.1g), stirs
Mix 1.5h, filter, 40 DEG C of dry 2.0h, obtain white solid (5.7g, yield: 91.9%), and X-ray powder diffraction figure such as attached drawing
Shown in 1.
Its X-ray powder diffraction data is as shown in table 1 below:
Table 1:
。
The preparation of the crystal form of 2 L-arginine phenylacetate of embodiment
(1) preparation of L-arginine phenylacetate: by L-arginine (3.48g, 20mmol) and phenylacetic acid (2.99g,
It 22mmol) is dissolved in ethyl alcohol (27.84ml), is warming up to 40 DEG C, there are a large amount of solids to be precipitated, is filtered, it is dry, obtain L-arginine benzene second
Hydrochlorate solid powder.
(2) L-arginine phenylacetate solid powder (5.5g) prepared by step 1) is added to 90% ethanol water
It is heated to flowing back in (29.4ml), solid is entirely molten, is cooled to 0 DEG C, stirs 1.5h, filtering, and 40 DEG C of dry 2.0h obtain white crystalline substance
Body, X-ray powder diffraction figure are identical as attached drawing 1.
The preparation of the crystal form of 3 L-arginine phenylacetate of embodiment
L-arginine (3.48g, 20mmol) and phenylacetic acid (2.99g, 22mmol) are added to 95% ethyl alcohol
In (20.88ml) solution, stirring is warming up to 40 DEG C, continues insulated and stirred 0.1h, has a large amount of solids to be precipitated, and 95% ethyl alcohol is added
(20.88ml) is heated to flowing back, and stirring, solid is entirely molten, is cooled to 0 DEG C, stirs 3h, filtering, and 40 DEG C of dry 2.0h are obtained white
(5.4g, yield: 87.2%), X-ray powder diffraction figure is identical as attached drawing 1 for color solid.
The preparation of the crystal form of 4 L-arginine phenylacetate of embodiment
L-arginine (3.48g, 20mmol) and phenylacetic acid (2.99g, 22mmol) are added to 90% ethanol water
In (20.88ml), stirring is warming up to 10 DEG C, continues insulated and stirred 5h, has a large amount of solids to be precipitated, and 90% ethanol water is added
(8.5ml) is heated to flowing back, and solid is entirely molten, is cooled to -20 DEG C, stirs 0.5h, filtering, and 40 DEG C of dry 2.0h obtain white crystalline substance
(5.5g, yield: 88.7%), X-ray powder diffraction figure is identical as attached drawing 1 for body.
The preparation of the crystal form of 5 L-arginine phenylacetate of embodiment
L-arginine (3.48g, 20mmol) and phenylacetic acid (5.44g, 40mmol) are dissolved in 98% ethyl alcohol (20.88ml),
10 DEG C, insulated and stirred 5h are warming up to, there are a large amount of solids to be precipitated, is added 98% ethyl alcohol (7.0ml), is added water (3.3ml), is heated to
Reflux, solid is entirely molten, is cooled to 0 DEG C, is added crystal seed (0.1g), stirs 0.5h, filtering, and 40 DEG C of dry 2.0h obtain white crystalline substance
(5.3g, yield: 85.6%), X-ray powder diffraction figure is identical as attached drawing 1 for body.
The preparation of the crystal form of 6 L-arginine phenylacetate of embodiment
L-arginine (3.48g, 20mmol) and phenylacetic acid (4.08g, 30mmol) are added to 90% ethanol water
In (17.40ml), stirring is warming up to 80 DEG C, continues insulated and stirred 3h, has a large amount of solids to be precipitated, is heated to flowing back, solid is complete
It is molten, 30 DEG C are cooled to, stirs 2.5h, filtering, 40 DEG C of dry 2.0h, obtaining white crystal, (5.6g, yield: 90.3%), X- is penetrated
Line powder diagram is identical as attached drawing 1.
Comparative example 1
17.42g L-arginine (0.1mol, 1.0eq.) is added into 250ml there-necked flask, 100ml ethyl alcohol is stirred at room temperature
30min；13.61g phenylacetic acid (0.1mol, 1.0eq.) is added into above-mentioned solution, nitrogen protection is stirred at room temperature, and solid is rapid
Dissolution after reaction solution becomes clarification, continues to stir 20min, evaporating solvent under reduced pressure at 35 DEG C obtains white solid 20.00g, this is white
Color solid is exposed at easy to absorb moisture in air.Its X-ray powder diffraction figure is as shown in Fig. 2.
Its X-ray powder diffraction data is as shown in table 2 below:
Table 2
。
It should be noted that the foregoing is merely illustrative of the preferred embodiments of the present invention, it is not intended to limit the invention, it is all
Made any modifications, equivalent replacements, and improvements etc. within the spirit and principles in the present invention should be included in guarantor of the invention
Within the scope of shield.
Claims (4)
1. a kind of crystal form of L-arginine phenylacetate (Formulas I),
It is characterized in that, the crystal form has X-ray powder diffraction figure as shown in Figure 1.
2. the preparation method of the crystal form of L-arginine phenylacetate described in a kind of claim 1, which is characterized in that can also pass through
After reaction by L-arginine and phenylacetic acid, C is directly added into reaction solution1~3Alcoholic solution is crystallized, and L-arginine is obtained
The crystal form of phenylacetate, specifically includes the following steps:
1) L-arginine and phenylacetic acid, are added to C with the molar ratio of 1:1~1:21~3In alcoholic solution, 10~80 DEG C are warming up to,
Stirring is reacted 0.1~5 hour；
2), C is added into the solution of step 1)1~3Alcoholic solution to L-arginine 5~20 times of envelope-bulk to weight ratio, be heated to reflux to
Solid is entirely molten, is cooled to -20 DEG C~30 DEG C, optional addition or is added without crystal seed, stirs 0.5~3h, filters, dry, obtains
White solid,
The C1~3Alcoholic solution is the ethanol water of 90%~100% volume ratio.
3. preparation method according to claim 2, which is characterized in that can also be heated to reflux in step 2) entirely molten to solid
Before, the water of 1%~12% ethyl alcohol volume is added into crystallizing system.
4. the L-arginine phenylacetate with crystal form described in claim 1, in preparation for preventing or treating liver property brain
Purposes in the drug of disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410475736.4A CN105481725B (en) | 2014-09-18 | 2014-09-18 | The crystal form and preparation method thereof of L-arginine phenylacetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410475736.4A CN105481725B (en) | 2014-09-18 | 2014-09-18 | The crystal form and preparation method thereof of L-arginine phenylacetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105481725A CN105481725A (en) | 2016-04-13 |
| CN105481725B true CN105481725B (en) | 2019-01-22 |
Family
ID=55669047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410475736.4A Active CN105481725B (en) | 2014-09-18 | 2014-09-18 | The crystal form and preparation method thereof of L-arginine phenylacetate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105481725B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421432A (en) * | 2009-04-03 | 2012-04-18 | 欧塞拉治疗有限公司 | L-ornithine phenyl acetate and methods of making thereof |
| CN102993037A (en) * | 2012-11-20 | 2013-03-27 | 万红贵 | Preparation method for L-ornithine phenylacetate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009902A (en) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compounds for reducing hyperammonemia in patients having cirrhosis or any inability for eliminating ammonium. |
-
2014
- 2014-09-18 CN CN201410475736.4A patent/CN105481725B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421432A (en) * | 2009-04-03 | 2012-04-18 | 欧塞拉治疗有限公司 | L-ornithine phenyl acetate and methods of making thereof |
| CN104230730A (en) * | 2009-04-03 | 2014-12-24 | 欧塞拉治疗有限公司 | L-ornithine phenyl acetate and methods of making thereof |
| CN102993037A (en) * | 2012-11-20 | 2013-03-27 | 万红贵 | Preparation method for L-ornithine phenylacetate |
Non-Patent Citations (2)
| Title |
|---|
| L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy;R. Jalan et al;《Medical Hypotheses》;20071231;第69卷(第5期);1064-1069 |
| 一种新型治疗肝性脑病的药物:L-鸟氨酸苯乙酸;万红贵等;《中国新药杂志》;20131231;第22卷(第11期);1274-1277 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105481725A (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102249975B (en) | (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I and preparation method and application thereof | |
| JP5860821B2 (en) | Chlorite formulation and method and use of this preparation | |
| AU2011312042B2 (en) | Methods of making L-ornithine phenyl acetate | |
| WO2008031284A1 (en) | A process for resolution of 5-methyltetrahydrofolic acid and its salification | |
| ES2548881T3 (en) | Dihydroetorphins and their preparation | |
| CN102180832A (en) | Compound for protecting cerebral ischemia and preparation method thereof | |
| KR20150142691A (en) | Tetrandrine family pharmaceutical formulations and method | |
| CN114081881A (en) | Organic acid lithium amino acid salt, crystal form, composition and application | |
| ES2278297T3 (en) | USE OF DERIVATIVES OF 2-AMINO-2H-QUINAZOLINE FOR THE PRODUCTION OF THERAPEUTIC AGENTS. | |
| CN105481725B (en) | The crystal form and preparation method thereof of L-arginine phenylacetate | |
| CN102924295B (en) | Bromhexine hydrochloride crystal as well as preparation method and application of crystal | |
| CN103191051B (en) | Nelarabine injection composition and preparation method thereof | |
| CN104418818B (en) | Parecoxib sodium anhydrous compound | |
| CN102746227B (en) | Dimemorfan phosphate crystal form II and preparation method thereof, and pharmaceutical composition | |
| Mann et al. | β β'β"-Triaminotriethylamine and its complex metallic compounds | |
| CN104974050A (en) | Water-soluble butylphthalide prodrug choline salt, preparation method therefor and application thereof in medicine | |
| CN104370792B (en) | Oxiracetam compound | |
| CN114105888B (en) | Eutectic crystal of propylthiouracil and nutrient micromolecule with antioxidant activity and preparation method thereof | |
| CN105439889A (en) | Vanillylamine type new compound as well as preparation method and medical appliance thereof | |
| CN107344920A (en) | A kind of Peramivir sesquialter hydrate compound | |
| CN105985252A (en) | Aspartic acid-ornithine crystal IV and preparation method thereof | |
| RU2045268C1 (en) | Antihistamine and antiallergic agent and method for preparing of glutaminate of hinuclidise-3-diphenylcarbinol as solution for injections | |
| CN103396376B (en) | A kind of antibacterial anti-cancer active compound | |
| CN102516106B (en) | Aspartic acid-ornithine compound | |
| ES2391738B1 (en) | Tramadol and diflunisal salts and their crystalline form in the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Building C25, nanotechnology Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Patentee after: Borui biomedical (Suzhou) Co.,Ltd. Patentee after: Borui Pharmaceutical (Suzhou) Co., Ltd Address before: Building C25, nanotechnology Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Patentee before: Borui biomedical (Suzhou) Co.,Ltd. Patentee before: XINTAI PHARMACEUTICAL (SUZHOU) Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |